1930 Marlton Pike E, Suite H-42 Cherry Hill, NJ 08003

References – Ketamine For Intractable Headaches

1. Schulman EA, Lake AE 3rd, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48(6):778-782.

2. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609.

3. Lipton RB, Bigal ME. Toward an epidemiology of refractory migraine: current knowledge and issues for future research. Headache. 2008;48(6):791-798.

4. Sinner B, Graf BM. Ketamine. In: Schüttler J, Schwilden H, eds. Modern Anesthetics. Springer; 2008:313-333.

5. Morgan CJ, Curran HV. Ketamine use: a review. Addiction. 2012;107(1):27-38.

6. Pai A, Heining M. Ketamine. Contin Ed Anaesth Crit Care Pain. 2007;7(2):59-63. doi:10.1093/bjaceaccp/mkm008

7. Joëls M, Baram TZ. The neuro-symphony of stress. Nat Rev Neurosci. 2009;10(6):459-466.

8. Peterlik D, Flor PJ, Uschold-Schmidt N. The emerging role of metabotropic glutamate receptors in the pathophysiology of chronic stress-related disorders. Curr Neuropharmacol. 2016;14(5):514-539.

9. Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation? Pharmacol Ther. 2018;190:148-158.

10. Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011;13(1):22-37.

11. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622.

12. Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia. 2007;27(12):1427-1439.

13. Martínez-Rodríguez R, Tonda A, Gragera RR, et al. Synaptic and non-synaptic immunolocalization of GABA and glutamate acid decarboxylase (GAD) in cerebellar cortex of rat. Cell Mol Biol. 1993;39(1):115-123.

14. de Almeida LM, Piñeiro CC, Leite MC, et al. Resveratrol increases glutamate uptake, glutathione content, and S100B secretion in cortical astrocyte cultures. Cell Mol Neurobiol. 2007;27(5):661-668.

15. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia. 2004;24(9):735-739.

16. Ferrari A, Spaccapelo L, Pinetti D, Tacchi R, Bertolini A. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia. 2009;29(4):423-429.

17. Peeters M, Gunthorpe MJ, Strijbos PJ, Goldsmith P, Upton N, James MF. Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther. 2007;321(2):564-572.

18. Santos E, Schöll M, Sanchez-Porras R, et al. Cortical spreading depression dynamics can be studied using intrinsic optical signal imaging in gyrencephalic animal cortex. Acta Neurochir Suppl. 2013;118:93-97.

19. Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):e852-e57. doi:10.4088/JCP.17f11738

20. Pribish A, Wood N, Kalava A. A review of nonanesthetic uses of ketamine. Anesthesiol Res Pract. 2020;2020:5798285. doi:10.1155/2020/5798285

21. Ahern TL, Herring AA, Miller S, Frazee BW. Low-dose ketamine infusion for emergency department patients with severe pain. Pain Med. 2015;16(7):1402-1409.

22. Galinski M, Dolveck F, Combes X, et al. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007;25(4):385-390.

23. Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: what is the evidence? Curr Opin Support Palliat Care. 2017;11(2):88-92.

24. Culp C, Kim HK, Abdi S. Ketamine use for cancer and chronic pain management. Front Pharmacol. 2021;11:599721. doi:10.3389/fphar.2020.599721

25. Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A. Treatment of severe mucositis pain with oral ketamine mouthwash. Support Care Cancer. 2017;25(7):2215-2219.

26. Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth. 1996;43(4):379-383.

27. Lauretti GR, Lima IC, Reis MP, et al. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology. 1999;90(6):1528-1533.

28. Connolly SB, Prager JP, Harden RN. A systematic review of ketamine for complex regional pain syndrome. Pain Med. 2015;16(5):943-969.

29. Duong S, Bravo D, Todd KJ, Finlayson RJ, Tran Q. Treatment of complex regional pain syndrome: an updated systematic review and narrative synthesis. Can J Anaesth. 2018;65(6):658-684.

30. Polomano RC, Buckenmaier CC 3rd, Kwon KH, et al. Effects of low-dose IV ketamine on peripheral and central pain from major limb injuries sustained in combat. Pain Med. 2013;14(7):1088-1100.

31. Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80(7):642-647.

32. Pomeroy JL, Marmura MJ, Nahas SJ, et al. Ketamine infusions for treatment refractory headache. Headache. 2017;57(2):276-282.

33. Lauritsen C, Mazuera S, Lipton RB, Ashina S. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016;17(1):106.

34. Nicolodi M, Sicuteri F. Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Clin Pharmacol Res. 1995;15(5-6):181-189.

35. Etchison AR, Bos L, Ray M, et al. Low-dose ketamine does not improve migraine in the emergency department: a randomized placebo-controlled trial. West J Emerg Med. 2018;19(6):952-960.

36. Mangnus TJP, Bharwani KD, Stronks DL, Dirckx M, Huygen FJPM. Ketamine therapy for chronic pain in the Netherlands: a nationwide survey. Scand J Pain. 2021;22(1):97-105.

37. Voute M, Riant T, Amodéo JM, et al. Ketamine in chronic pain: a Delphi survey. Eur J Pain. 2022;26(4):873-887

38. Aroke EN, Crawford SL, Dungan JR. Pharmacogenetics of ketamine-induced emergence phenomena: a pilot study. Nurs Res. 2017;66(2):105-114.

39. Pomarol-Clotet E, Honey GD, Murray GK, et al. Psychological effects of ketamine in healthy volunteers: phenomenological study. Br J Psychiatry. 2006;189:173-179.

40. Weiler MA, Thaker GK, Lahti AC, et al. Ketamine effects on eye movements. Neuropsychopharmacology. 2000;23(6):645-653.

41. Liebe T, Li S, Lord A, et al. Factorsinfluencing the cardiovascular response to subanesthetic ketamine: a randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2017;20(11):909-918.

42. Kunst G, Martin E, Graf BM, Vahl CF. Actions of ketamine and its isomers on contractility and calcium transients in human myocardium. Anesthesiology. 1999;90(5):1363-1371.

43. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357-367.

44. Zhou YL, Liu WJ, Wang CY, et al. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. J Psychopharmacol. 2021;35(2):159-167.

45. National Institute of Diabetes and Digestive and Kidney Diseases. Ketamine. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

46. Zhu X, Kohan LR, Goldstein RB. Substantial elevation of liver enzymes during ketamine infusion: a case report. A A Pract. 2020;14(8):e01239. doi:10.1213/xaa.0000000000001239

47. Noppers IM, Niesters M, Aarts L, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011;152(9):2173-2178.

48. Meng E, Wu S, Cha T, Sun G, Yu D, Chang S. A murderer of young bladders: ketamine-associated cystitis. Urol Sci. 2013;24(4):113-116. doi:https://doi.org/10.1016/j.urols.2013.09.001

49. Baker SC, Shabir S, Georgopoulos NT, Southgate J. Ketamine-induced apoptosis in normal human urothelial cells: a direct, N-methyl-D-aspartate receptor-independent pathway characterized by mitochondrial stress. Am J Pathol. 2016;186(5):1267-1277.

50. Chu PS, Ma WK, Wong SC, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int. 2008;102(11):1616-1622.

51. Findeis H, Sauer C, Cleare A, Bauer M, Ritter P. Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology. 2020;237(11):3295-3302.

52. Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521-546.

53. Commonwealth of Pennsylvania. Guidelines for safe administration of low-dose ketamine. Published 2020. Accessed July 24, 2022. https://www.health.pa.gov/topics/Documents/Opioids/Ketamine%20Guidelines.pdf


The authors report no disclosures.